Update on medical therapy for male LUTS

doi:10.5489/cuaj.2310

Review

. 2014 Jul;8(7-8 Suppl 5):S148-50.

doi: 10.5489/cuaj.2310.

Update on medical therapy for male LUTS

Sidney B Radomski¹

Affiliations

PMID: 25243039
PMCID: PMC4145697
DOI: 10.5489/cuaj.2310

Review

Update on medical therapy for male LUTS

Sidney B Radomski. Can Urol Assoc J. 2014 Jul.

. 2014 Jul;8(7-8 Suppl 5):S148-50.

doi: 10.5489/cuaj.2310.

Author

Sidney B Radomski¹

Affiliation

¹ Professor of Surgery (Urology), University of Toronto, Toronto Western Hospital, Toronto, ON.

PMID: 25243039
PMCID: PMC4145697
DOI: 10.5489/cuaj.2310

Abstract

The medical management of lower urinary tract symptoms (LUTS) is aimed at addressing voiding and storage symptoms in patients with benign prostate hyperplasia (BPH) symptoms with or without an over-active bladder (OAB). Current available options for BPH include alpha-blockers, 5-alpha reductase inhibitors and phosphodiesterase type 5 inhibitors. For OAB, options include antimuscarinics, with or without an alpha-blocker, the beta-3-adrenergic agonist mirabegron and the synthetic diuretic desmopressin. With the availability of numerous options and combinations available for the treatment of LUTS, individual patient assessment is the key to optimal symptom control and management of adverse effects.

PubMed Disclaimer

Figures

**Fig. 1.**
Therapeutic algorithm for the management of lower urinary tract symptoms. Copyright © 2010 Canadian Urological Association. All rights reserved.

See this image and copyright information in PMC

Cited by

Predictive factors for alpha blocker use after transurethral prostatectomy: Can preoperative urodynamic outcome predict alpha blocker medication after surgery?
Kim SJ, Park SG, Pak S, Lee YG, Cho ST, Kwon O. Kim SJ, et al. PLoS One. 2022 Sep 21;17(9):e0274399. doi: 10.1371/journal.pone.0274399. eCollection 2022. PLoS One. 2022. PMID: 36129917 Free PMC article.
In utero and lactational PCB exposure drives anatomic changes in the juvenile mouse bladder.
Keil Stietz KP, Kennedy CL, Sethi S, Valenzuela A, Nunez A, Wang K, Wang Z, Wang P, Spiegelhoff A, Puschner B, Bjorling DE, Lein PJ. Keil Stietz KP, et al. Curr Res Toxicol. 2021;2:1-18. doi: 10.1016/j.crtox.2021.01.002. Epub 2021 Jan 12. Curr Res Toxicol. 2021. PMID: 34337439 Free PMC article.
Phosphodiesterase inhibitors for lower urinary tract symptoms consistent with benign prostatic hyperplasia.
Pattanaik S, Mavuduru RS, Panda A, Mathew JL, Agarwal MM, Hwang EC, Lyon JA, Singh SK, Mandal AK. Pattanaik S, et al. Cochrane Database Syst Rev. 2018 Nov 16;11(11):CD010060. doi: 10.1002/14651858.CD010060.pub2. Cochrane Database Syst Rev. 2018. PMID: 30480763 Free PMC article.
The Effect of LUTS/BPH and Treatments on Ejaculatory Function.
Herberts M, Butcher M, Köhler T. Herberts M, et al. Curr Urol Rep. 2016 Jul;17(7):48. doi: 10.1007/s11934-016-0604-4. Curr Urol Rep. 2016. PMID: 27105993 Review.

References

1. McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185:1793–803. doi: 10.1016/j.juro.2011.01.074. - DOI - PubMed
1. Parsons JK, Bergstrom J, Silberstein J, et al. Prevalence and characteristics of lower urinary tract symptoms in men aged > or = 80 years. Urology. 2008;72:318–21. doi: 10.1016/j.urology.2008.03.057. - DOI - PMC - PubMed
1. McVary KT, Roehrborn CG, Avins AL. American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH) American Urological Association Education and Research, Inc; 2010.
1. Nickel JC, Méndez-Probst CE, Whelan TF, et al. 2010 Update: Guidelines for the management of benign prostatic hyperplasia. Can Urol Assoc J. 2010;4:310–6. doi: 10.5489/cuaj.10124. - DOI - PMC - PubMed
1. Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60:434–41. doi: 10.1016/S0090-4295(02)01905-2. - DOI - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations

[1] McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185:1793–803. doi: 10.1016/j.juro.2011.01.074. - DOI - PubMed

[2] McVary KT, Roehrborn CG, Avins AL, et al. Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol. 2011;185:1793–803. doi: 10.1016/j.juro.2011.01.074. - DOI - PubMed

[3] Parsons JK, Bergstrom J, Silberstein J, et al. Prevalence and characteristics of lower urinary tract symptoms in men aged > or = 80 years. Urology. 2008;72:318–21. doi: 10.1016/j.urology.2008.03.057. - DOI - PMC - PubMed

[4] Parsons JK, Bergstrom J, Silberstein J, et al. Prevalence and characteristics of lower urinary tract symptoms in men aged > or = 80 years. Urology. 2008;72:318–21. doi: 10.1016/j.urology.2008.03.057. - DOI - PMC - PubMed

[5] McVary KT, Roehrborn CG, Avins AL. American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH) American Urological Association Education and Research, Inc; 2010.

[6] McVary KT, Roehrborn CG, Avins AL. American Urological Association Guideline: Management of Benign Prostatic Hyperplasia (BPH) American Urological Association Education and Research, Inc; 2010.

[7] Nickel JC, Méndez-Probst CE, Whelan TF, et al. 2010 Update: Guidelines for the management of benign prostatic hyperplasia. Can Urol Assoc J. 2010;4:310–6. doi: 10.5489/cuaj.10124. - DOI - PMC - PubMed

[8] Nickel JC, Méndez-Probst CE, Whelan TF, et al. 2010 Update: Guidelines for the management of benign prostatic hyperplasia. Can Urol Assoc J. 2010;4:310–6. doi: 10.5489/cuaj.10124. - DOI - PMC - PubMed

[9] Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60:434–41. doi: 10.1016/S0090-4295(02)01905-2. - DOI - PubMed

[10] Roehrborn CG, Boyle P, Nickel JC, et al. Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia. Urology. 2002;60:434–41. doi: 10.1016/S0090-4295(02)01905-2. - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Update on medical therapy for male LUTS

Affiliation

Update on medical therapy for male LUTS

Author

Affiliation

Abstract

Figures

Similar articles

Cited by

References

Publication types

LinkOut - more resources

Full Text Sources

Other Literature Sources